Study Compares PDR, DME Risk Between Two Popular Diabetes Drugs

Patients taking GLP-1 agonists had a higher rate of progression to proliferative retinopathy and new-onset macular edema than those on SGLT-2 inhibitors.

Glucose Control, Renal Function Help Predict Anti-VEGF Treatment Response in DME

Patients with low glomerular filtration rates and high glycated hemoglobin levels fared worse in this study, highlighting the need for continuous monitoring of systemic health.

Academy of Ophthalmology Endorses Teleretinal Screening for Diabetic Retinopathy

While this modality was not as robust in detecting DME, studies show it is both accurate and cost-effective for DR.

Diabetes Patients Experience Choroidal Microvascular Alterations Before DR

This was observed in early cases of the disease without associated retinopathy.

Severity Levels of Carotid Artery Stenosis Impact Diabetic Retinopathy

Clinicians should be mindful of possible atherosclerotic changes in patients with PDR, study argues.

Thyroid Function-related Hormones a Risk Factor for DR

Study shows that alterations in patients with normal thyroid function may affect glucose and lipid metabolism, increasing the risk of DR.

Certain Lipid Abnormalities May Reduce DR Risk in Type 2 Diabetes

Though dyslipidemia is associated with this complication, new research shows that reduced HDL levels and elevated cholesterol and triglycerides may actually have a protective effect.

Choriocapillaris May Be Earliest Affected, Most Vulnerable Region in DR

Study shows impairment here is associated with HbA1c levels and can precede clinical manifestations.

Diabetic Eye Disease Research: Many Dollars, Few Drugs

Nearly $1 billion was spent from 2012 to 2021—practically all by the NIH—and the number of published papers on the topic increased 3.5-fold, but new drug approvals were scant.

Study Supports Bevacizumab as First-line DME Therapy

This affordable anti-VEGF conferred real-world visual gains and cost savings with fewer injections over time.

Upcoming Events

May 2, 2024

Rethinking Dry Eye Disease: A Contemporary Approach to a Complex Condition
Location: Virtual
Presenters:  Kamran Riaz, MD, and Melissa Barnett, OD
Webinar: 7:00pm ET

Sponsored by Bausch + Lomb

Register here

May 17-19, 2024

New Technologies & Treatments in Eye Care and Intrepid Eye Society's Spring Conference

Location: Omni La Costa, Carlsbad, California
Co-Chairs: Paul M. Karpecki, OD, and Selina McGee, OD

Register here

June 4, 2024

Rethinking Dry Eye Disease: A Contemporary Approach to a Complex Condition
Location: Virtual
Presenters:  Karl G. Stonecipher, MD, and Jessica Steen, OD
Webinar: 8:00pm ET

Sponsored by Bausch + Lomb

Register here